{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:54:13Z","timestamp":1791950053946,"version":"4.3.4"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["43400003"],"award-info":[{"award-number":["43400003"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["917.11.337"],"award-info":[{"award-number":["917.11.337"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001829","name":"Universiteit Utrecht","doi-asserted-by":"publisher","award":["2013-6426"],"award-info":[{"award-number":["2013-6426"]}],"id":[{"id":"10.13039\/501100001829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001829","name":"Universiteit Utrecht","doi-asserted-by":"publisher","award":["2014-6790"],"award-info":[{"award-number":["2014-6790"]}],"id":[{"id":"10.13039\/501100001829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001829","name":"Universiteit Utrecht","doi-asserted-by":"publisher","award":["2015-7601"],"award-info":[{"award-number":["2015-7601"]}],"id":[{"id":"10.13039\/501100001829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001829","name":"Universiteit Utrecht","doi-asserted-by":"publisher","award":["2018-11393"],"award-info":[{"award-number":["2018-11393"]}],"id":[{"id":"10.13039\/501100001829","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gadeta"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0558-4","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T15:44:30Z","timestamp":1552578270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Evaluating in vivo efficacy \u2013 toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells"],"prefix":"10.1136","volume":"7","author":[{"given":"Inez","family":"Johanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy","family":"Straetemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Heijhuurs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tineke","family":"Aarts-Riemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kan","family":"Norell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bongiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"de Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Sebestyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Kuball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,3,12]]},"reference":[{"key":"558_CR1","doi-asserted-by":"crossref","unstructured":"Chabannon C, Kuball J, Bondanza A, Dazzi F, Pedrazzoli P, Toubert A, et al. Hematopoietic stem cell transplantation in its 60s: a platform for cellular therapies. Sci Transl Med. 2018;10(436).","DOI":"10.1126\/scitranslmed.aap9630"},{"issue":"8","key":"558_CR2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36(8):494\u2013502.","journal-title":"Trends Immunol"},{"issue":"2","key":"558_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1084\/jem.20082487","volume":"206","author":"J Kuball","year":"2009","unstructured":"Kuball J, Hauptrock B, Malina V, Antunes E, Voss RH, Wolfl M, et al. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med. 2009;206(2):463\u201375.","journal-title":"J Exp Med"},{"issue":"6","key":"558_CR4","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2006-05-023069","volume":"109","author":"J Kuball","year":"2007","unstructured":"Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood. 2007;109(6):2331\u20138.","journal-title":"Blood."},{"issue":"8","key":"558_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/17474086.2016.1203251","volume":"9","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Maloney DG. Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape. Expert Rev Hematol. 2016;9(8):719\u201321.","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"558_CR6","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","volume":"32","author":"H Jetani","year":"2018","unstructured":"Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Meijide JB, et al. CAR T-cells targeting FLT3 have potent activity against FLT3(\u2212)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia. 2018;32(5):1168\u201379.","journal-title":"Leukemia."},{"issue":"11","key":"558_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017075","volume":"7","author":"C Lonez","year":"2017","unstructured":"Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, et al. Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ Open. 2017;7(11):e017075.","journal-title":"BMJ Open"},{"issue":"7463","key":"558_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415\u201321.","journal-title":"Nature."},{"issue":"3","key":"558_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3324\/haematol.2010.025916","volume":"96","author":"MM Loenen van","year":"2011","unstructured":"van Loenen MM, de Boer R, Hagedoorn RS, van Egmond EH, Falkenburg JH, Heemskerk MH. Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies. Haematologica. 2011;96(3):477\u201381.","journal-title":"Haematologica."},{"issue":"1","key":"558_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2010-12-325993","volume":"118","author":"V Marcu-Malina","year":"2011","unstructured":"Marcu-Malina V, Heijhuurs S, van BM, Hartkamp L, Strand S, Sebestyen Z, et al. Redirecting alphabeta T cells against cancer cells by transfer of a broadly tumor-reactive gammadeltaT-cell receptor. Blood. 2011;118(1):50\u20139.","journal-title":"Blood."},{"issue":"2","key":"558_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1084\/jem.20021500","volume":"197","author":"HJ Gober","year":"2003","unstructured":"Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De LG. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197(2):163\u20138.","journal-title":"J Exp Med"},{"issue":"9","key":"558_CR12","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.celrep.2016.04.081","volume":"15","author":"Z Sebestyen","year":"2016","unstructured":"Sebestyen Z, Scheper W, Vyborova A, Gu S, Rychnavska Z, Schiffler M, et al. RhoB mediates Phosphoantigen recognition by Vgamma9Vdelta2 T cell receptor. Cell Rep. 2016;15(9):1973\u201385.","journal-title":"Cell Rep"},{"key":"558_CR13","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fimmu.2014.00636","volume":"5","author":"DC Deniger","year":"2014","unstructured":"Deniger DC, Moyes JS, Cooper LJ. Clinical applications of gamma delta T cells with multivalent immunity. Front Immunol. 2014;5:636.","journal-title":"Front Immunol"},{"issue":"2","key":"558_CR14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384.013k07_384_392","volume":"96","author":"V Kunzmann","year":"2000","unstructured":"Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96(2):384\u201392.","journal-title":"Blood."},{"issue":"6","key":"558_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/leu.2013.378","volume":"28","author":"W Scheper","year":"2014","unstructured":"Scheper W, Grunder C, Straetemans T, Sebestyen Z, Kuball J. Hunting for clinical translation with innate-like immune cells and their receptors. Leukemia. 2014;28(6):1181\u201390.","journal-title":"Leukemia."},{"key":"558_CR16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3389\/fimmu.2014.00601","volume":"5","author":"W Scheper","year":"2014","unstructured":"Scheper W, Sebestyen Z, Kuball J. Cancer immunotherapy using gammadeltaT cells: dealing with diversity. Front Immunol. 2014;5:601.","journal-title":"Front Immunol"},{"issue":"17","key":"558_CR17","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1158\/1078-0432.CCR-14-2860","volume":"21","author":"T Straetemans","year":"2015","unstructured":"Straetemans T, Grunder C, Heijhuurs S, Hol S, Slaper-Cortenbach I, Bonig H, et al. Untouched GMP-ready purified engineered immune cells to treat Cancer. Clin Cancer Res. 2015;21(17):3957\u201368.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"558_CR18","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1182\/blood-2012-05-432427","volume":"120","author":"C Grunder","year":"2012","unstructured":"Grunder C, van DS, Hol S, Drent E, Straetemans T, Heijhuurs S, et al. gamma9 and delta2CDR3 domains regulate functional avidity of T cells harboring gamma9delta2TCRs. Blood. 2012;120(26):5153\u201362.","journal-title":"Blood."},{"key":"558_CR19","doi-asserted-by":"crossref","unstructured":"Gu S, Borowska MT, Boughter CT, Adams EJ. Butyrophilin3A proteins and Vgamma9Vdelta2 T cell activation. Semin Cell Dev Biol. 2018.","DOI":"10.1016\/j.semcdb.2018.02.007"},{"issue":"35","key":"558_CR20","doi-asserted-by":"publisher","first-page":"E7311","DOI":"10.1073\/pnas.1707547114","volume":"114","author":"S Gu","year":"2017","unstructured":"Gu S, Sachleben JR, Boughter CT, Nawrocka WI, Borowska MT, Tarrasch JT, et al. Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vgamma9Vdelta2 T cell activation. Proc Natl Acad Sci U S A. 2017;114(35):E7311\u2013E20.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"558_CR21","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2012-05-430470","volume":"120","author":"C Harly","year":"2012","unstructured":"Harly C, Guillaume Y, Nedellec S, Peigne CM, Monkkonen H, Monkkonen J, et al. Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gammadelta T-cell subset. Blood. 2012;120(11):2269\u201379.","journal-title":"Blood."},{"issue":"39","key":"558_CR22","doi-asserted-by":"publisher","first-page":"32780","DOI":"10.1074\/jbc.M112.384354","volume":"287","author":"A Palakodeti","year":"2012","unstructured":"Palakodeti A, Sandstrom A, Sundaresan L, Harly C, Nedellec S, Olive D, et al. The molecular basis for modulation of human Vgamma9Vdelta2 T cell responses by CD277\/butyrophilin-3 (BTN3A)-specific antibodies. J Biol Chem. 2012;287(39):32780\u201390.","journal-title":"J Biol Chem"},{"issue":"9","key":"558_CR23","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/ni.2665","volume":"14","author":"S Vavassori","year":"2013","unstructured":"Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, El Daker S, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human gammadelta T cells. Nat Immunol. 2013;14(9):908\u201316.","journal-title":"Nat Immunol"},{"key":"558_CR24","doi-asserted-by":"crossref","unstructured":"Braham MVJ, Minnema MC, Aarts T, Sebestyen Z, Straetemans T, Vyborova A, et al. Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model. Oncoimmunology. 2018:e1434465.","DOI":"10.1080\/2162402X.2018.1434465"},{"issue":"10","key":"558_CR25","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/leu.2010.158","volume":"24","author":"M Wunderlich","year":"2010","unstructured":"Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, et al. AML xenograft efficiency is significantly improved in NOD\/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia. 2010;24(10):1785\u20138.","journal-title":"Leukemia."},{"issue":"4","key":"558_CR26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S1074-7613(03)00272-3","volume":"19","author":"M Gleimer","year":"2003","unstructured":"Gleimer M, Parham P. Stress management: MHC class I and class I-like molecules as reporters of cellular stress. Immunity. 2003;19(4):469\u201377.","journal-title":"Immunity."},{"issue":"32","key":"558_CR27","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"558_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"558_CR29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863\u201371.","journal-title":"Blood."},{"key":"558_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.9","volume":"3","author":"R Novosiadly","year":"2016","unstructured":"Novosiadly R, Kalos M. High-content molecular profiling of T-cell therapy in oncology. Mol Ther Oncolytics. 2016;3:16009.","journal-title":"Mol Ther Oncolytics"},{"key":"558_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ebiom.2016.06.028","volume":"10","author":"J Xia","year":"2016","unstructured":"Xia J, Hu Z, Yoshihara S, Li Y, Jin CH, Tan S, et al. Modeling human leukemia immunotherapy in humanized mice. EBioMedicine. 2016;10:101\u20138.","journal-title":"EBioMedicine."},{"issue":"5824","key":"558_CR32","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1139851","volume":"316","author":"F Barabe","year":"2007","unstructured":"Barabe F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science. 2007;316(5824):600\u20134.","journal-title":"Science."},{"issue":"1","key":"558_CR33","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-017-0470-7","volume":"10","author":"Y Lai","year":"2017","unstructured":"Lai Y, Wei X, Lin S, Qin L, Cheng L, Li P. Current status and perspectives of patient-derived xenograft models in cancer research. J Hematol Oncol. 2017;10(1):106.","journal-title":"J Hematol Oncol"},{"issue":"17","key":"558_CR34","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1158\/0008-5472.CAN-13-1069","volume":"73","author":"D Siolas","year":"2013","unstructured":"Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013;73(17):5315\u20139.","journal-title":"Cancer Res"},{"issue":"11","key":"558_CR35","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/leu.2009.143","volume":"23","author":"PV Sanchez","year":"2009","unstructured":"Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, Swider CR, et al. A robust xenotransplantation model for acute myeloid leukemia. Leukemia. 2009;23(11):2109\u201317.","journal-title":"Leukemia."},{"issue":"4","key":"558_CR36","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/sj.bmt.1702169","volume":"25","author":"D Frasca","year":"2000","unstructured":"Frasca D, Guidi F, Arbitrio M, Pioli C, Poccia F, Cicconi R, et al. Hematopoietic reconstitution after lethal irradiation and bone marrow transplantation: effects of different hematopoietic cytokines on the recovery of thymus, spleen and blood cells. Bone Marrow Transplant. 2000;25(4):427\u201333.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"558_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1084\/jem.20061115","volume":"204","author":"M Serafini","year":"2007","unstructured":"Serafini M, Dylla SJ, Oki M, Heremans Y, Tolar J, Jiang Y, et al. Hematopoietic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoietic stem cells. J Exp Med. 2007;204(1):129\u201339.","journal-title":"J Exp Med"},{"issue":"6","key":"558_CR38","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1089\/152581602321080628","volume":"11","author":"SC Miller","year":"2002","unstructured":"Miller SC. Hematopoietic reconstitution of irradiated, stem cell-injected mice: early dynamics of restoration of the cell lineages of the spleen and bone marrow. J Hematother Stem Cell Res. 2002;11(6):965\u201370.","journal-title":"J Hematother Stem Cell Res"},{"key":"558_CR39","doi-asserted-by":"crossref","unstructured":"Gulley JL, Madan RA, Pachynski R, Mulders P, Sheikh NA, Trager J, et al. Role of antigen spread and distinctive characteristics of immunotherapy in Cancer treatment. J Natl Cancer Inst. 2017;109(4).","DOI":"10.1093\/jnci\/djw261"},{"key":"558_CR40","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3389\/fimmu.2018.01062","volume":"9","author":"T Straetemans","year":"2018","unstructured":"Straetemans T, Kierkels G, Doorn R, Jansen K, Heijhuurs S, dos Santos J, et al. GMP-grade manufacturing of T cells engineered to express a defined \u03b3\u03b4TCR. Frontier in Immunology. 2018;9:1062.","journal-title":"Frontier in Immunology"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0558-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0558-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0558-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:47:06Z","timestamp":1601056026000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0558-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["558"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0558-4","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,12]]},"assertion":[{"value":"17 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In vivo experiments were conducted according to Institutional Guidelines under acquired permission from the local Ethical Committee and per current Dutch laws on Animal Experimentation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JK received funding by Gadeta. JK and ZS are inventors on different patents with \u03b3\u03b4TCR sequences, recognition mechanism and isolation strategies. JK is CSO and shareholder of Gadeta.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"69"}}